<?xml version='1.0' encoding='utf-8'?>
<document id="26014906"><sentence text="Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection."><entity charOffset="43-54" id="DDI-PubMed.26014906.s1.e0" text="daclatasvir" /></sentence><sentence text="The treatment of hepatitis C virus (HCV) has evolved dramatically after the introduction of direct acting anti-virals" /><sentence text=" NS5A protein plays an important role in HCV replication and is an attractive target for drug development" /><sentence text="" /><sentence text="To review clinical studies on the efficacy and safety of direct-acting anti-virals regimens containing daclastavir, an NS5A inhibitor, in the treatment of chronic hepatitis C"><entity charOffset="103-114" id="DDI-PubMed.26014906.s5.e0" text="daclastavir" /></sentence><sentence text="" /><sentence text="A Medline search was undertaken to identify relevant literature using search terms including 'daclatasvir', 'HCV treatment' and 'NS5A inhibitors'" /><sentence text=" Furthermore, we scanned abstracts presented at the recent international meetings in liver disease, viral hepatitis and infectious disease, as well as the reference lists of the review articles to identify publications not retrieved by electronic searches" /><sentence text="" /><sentence text="Daclatasvir is the first-in-class HCV NS5A inhibitor that has been demonstrated in Phase I-III trials to have a potent anti-viral effect and clinical efficacy across multiple HCV genotypes (GT)"><entity charOffset="0-11" id="DDI-PubMed.26014906.s10.e0" text="Daclatasvir" /></sentence><sentence text=" Daclastavir is generally safe and well tolerated, with a low barrier to resistance and low potential for drug-drug interaction"><entity charOffset="1-12" id="DDI-PubMed.26014906.s11.e0" text="Daclastavir" /></sentence><sentence text=" When Daclastavir is added to PEG-IFN/RBV platform, sustained virological response (SVR) rates are increased significantly compared with PEG-IFN/RBV alone" /><sentence text=" The all-oral combination of Daclastavir/asunaprevir (ASV; protease inhibitor) has high SVR rates against GT1b, but less activity against GT1a"><entity charOffset="29-40" id="DDI-PubMed.26014906.s13.e0" text="Daclastavir" /><entity charOffset="41-52" id="DDI-PubMed.26014906.s13.e1" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.26014906.s13.e0" e2="DDI-PubMed.26014906.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26014906.s13.e0" e2="DDI-PubMed.26014906.s13.e1" /></sentence><sentence text=" Dual combination of Daclastavir/Sofosbuvir (SOF; nucleotide polymerase inhibitor) and triple combination of Daclastavir/ASV/beclabuvir (BCV; non-nucleoside polymerase inhibitor) have demonstrated &gt;90% SVR rates in both treatment naÃ¯ve and treatment-experienced patients with GT1"><entity charOffset="21-32" id="DDI-PubMed.26014906.s14.e0" text="Daclastavir" /><entity charOffset="33-43" id="DDI-PubMed.26014906.s14.e1" text="Sofosbuvir" /><entity charOffset="45-48" id="DDI-PubMed.26014906.s14.e2" text="SOF" /><entity charOffset="109-120" id="DDI-PubMed.26014906.s14.e3" text="Daclastavir" /><entity charOffset="125-135" id="DDI-PubMed.26014906.s14.e4" text="beclabuvir" /><entity charOffset="137-140" id="DDI-PubMed.26014906.s14.e5" text="BCV" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e0" e2="DDI-PubMed.26014906.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e0" e2="DDI-PubMed.26014906.s14.e1" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e0" e2="DDI-PubMed.26014906.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e0" e2="DDI-PubMed.26014906.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e0" e2="DDI-PubMed.26014906.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e0" e2="DDI-PubMed.26014906.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e1" e2="DDI-PubMed.26014906.s14.e1" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e1" e2="DDI-PubMed.26014906.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e1" e2="DDI-PubMed.26014906.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e1" e2="DDI-PubMed.26014906.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e1" e2="DDI-PubMed.26014906.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e2" e2="DDI-PubMed.26014906.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e2" e2="DDI-PubMed.26014906.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e2" e2="DDI-PubMed.26014906.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e2" e2="DDI-PubMed.26014906.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e3" e2="DDI-PubMed.26014906.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e3" e2="DDI-PubMed.26014906.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e3" e2="DDI-PubMed.26014906.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e4" e2="DDI-PubMed.26014906.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26014906.s14.e4" e2="DDI-PubMed.26014906.s14.e5" /></sentence><sentence text=" Furthermore, Daclastavir/SOF combination has also demonstrated up to 90% SVR rates in patients with GT3, and in those with human immunodeficiency virus coinfection, cirrhosis and post-transplant HCV recurrence with any GT"><entity charOffset="14-25" id="DDI-PubMed.26014906.s15.e0" text="Daclastavir" /><entity charOffset="26-36" id="DDI-PubMed.26014906.s15.e1" text="SOF" /><pair ddi="false" e1="DDI-PubMed.26014906.s15.e0" e2="DDI-PubMed.26014906.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26014906.s15.e0" e2="DDI-PubMed.26014906.s15.e1" /></sentence><sentence text=" Daclastavir/ASV/BCV has primarily demonstrated near 100% SVR rates in patients with GT4"><entity charOffset="1-12" id="DDI-PubMed.26014906.s16.e0" text="Daclastavir" /><entity charOffset="17-27" id="DDI-PubMed.26014906.s16.e1" text="BCV" /><pair ddi="false" e1="DDI-PubMed.26014906.s16.e0" e2="DDI-PubMed.26014906.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26014906.s16.e0" e2="DDI-PubMed.26014906.s16.e1" /></sentence><sentence text="" /><sentence text="Daclastavir-containing regimens, with or without PEG-IFN, have shown promising results in clinical trials, and present an excellent treatment option for those with chronic HCV and for multiple genotypes"><entity charOffset="0-11" id="DDI-PubMed.26014906.s18.e0" text="Daclastavir" /></sentence><sentence text="" /></document>